Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.

NCT00550420 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00550420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00550420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
October 1, 2007
Completion date
February 12, 2009
Enrollment
331 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease